- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05782504
Patient-centered Breast Cancer Teleprehabilitation (BC-PREHAB)
Patient-centered Teleprehabilitation for Women With Breast Cancer: a Feasibility Study
Surgery, the cornerstone of most cancer treatments, is associated with considerable postoperative complications. Adjusting patients' health behavior before surgery may have beneficial effects on postoperative outcomes.
Women (n=50) who will undergo breast surgery because of stage I-III breast cancer are eligible. All participants will receive multimodal patient-centered teleprehabilitation comprising of motivational interviewing, education, exercise therapy, and stress management.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Feasibility, participation rate, patient satisfaction, intervention safety, and treatment adherence will be monitored as primary outcomes. Fatigue, pain, quality of life (QoL), physical activity levels, perceived injustice, self-efficacy, and healthcare use are secondary outcomes and will be assessed by self-reported questionnaires at baseline, 0-, 2-, and 6 months post-intervention.
Proof of concept for using telecommunication and exercise therapy in prehabilitation prior to breast cancer surgery is available. We expect the proposed intervention to be feasible and effective at reducing fatigue, pain, perceived injustice, and healthcare use, and at improving treatment adherence, QoL, physical activity levels, and self-efficacy.
Effective prehabilitation interventions can reduce the long-term symptoms that arise/persist beyond treatment completion, improving patients' QoL. By using telecommunication technologies, socio-economic barriers can be reduced, making care accessible to all.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kenza Mostaqim, Dra.
- Phone Number: +3224774503
- Email: Kenza.Mostaqim@vub.be
Study Contact Backup
- Name: Eva Huysmans, Dr.
- Phone Number: +3224774503
- Email: Eva.Huysmans@vub.be
Study Locations
-
-
-
Genk, Belgium, 3600
- Recruiting
- Ziekenhuis Oost-Limburg
-
Contact:
- Eric de Jonge, Dr.
-
-
Brussels
-
Jette, Brussels, Belgium, 1020
- Recruiting
- Universitair Ziekenhuis Brussel
-
Contact:
- Jo Nijs, Prof. Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 years or older
- Scheduled for primary breast surgery because of stage I-III breast cancer
- Able to speak and read Dutch fluently
Exclusion Criteria:
- Stage IV breast cancer
- A medical contra-indication for physical activity
- Not being able to access a computer or mobile device at home
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment arm
4 treatment sessions, each lasting 60 minutes, within a 4-week perioperative period, with 2 preoperative (in the last 2 weeks before surgery) and 2 postoperative (in the first 2 weeks after surgery) sessions.
|
Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes. Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software. Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced. Motivational interviewing will be used during the whole intervention. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participation rate
Time Frame: one day before the start of the intervention
|
This will be calculated as the ratio of the number of patients participating in the study to the number of patients eligible for study participation.
Along with that, the participation rate for each of the secondary outcome measures (see further) at each of the time points (baseline and follow-up) will be recorded.
|
one day before the start of the intervention
|
|
Patient satisfaction with the teleprehabilitation intervention (feeling of contentment with the intervention)
Time Frame: within one week after completion of the intervention
|
This will be assessed using a questionnaire ending with an open question ('To what extent is this what you needed?
Please explain your answer') and the possibility to suggest alternative treatment content.
Patient satisfaction with teleprehabilitation will also be assessed using in-depth interviews with all study participants.
|
within one week after completion of the intervention
|
|
Incidence of treatment-emergent adverse events (safety and tolerability)
Time Frame: within one week after completion of the intervention
|
To examine the safety of the intervention, participants will be asked whether they experienced any side effects or unexpected events associated with the intervention after each treatment session.
|
within one week after completion of the intervention
|
|
Adherence to treatment (compliance rate)
Time Frame: within one week after completion of the intervention
|
The compliance rate for the teleprehabilitation sessions will be calculated as the ratio of the number of followed treatment sessions versus the number of planned treatment sessions.
Next to the supervised sessions, patients will also have sessions without direct supervision that they will have to carry out themselves at home (i.e., exercise sessions, relaxation exercises, and reading the information leaflet).
Patients will be asked to record these unsupervised therapy sessions in a personal logbook.
The compliance with these home exercise sessions is calculated as the ratio between the number of sessions performed and the number of sessions prescribed.
|
within one week after completion of the intervention
|
|
Feasibility of teleprehabilitation in the clinical setting by means of focus group discussions with stakeholders
Time Frame: through study completion, an average of 1 year
|
The feasibility of the patient-centered teleprehabilitation intervention in the clinical setting will be investigated using focus group discussions with all the involved care providers.
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue (feeling of tiredness or lack of energy)
Time Frame: one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
Fatigue is one of the most debilitating symptoms in patients with breast cancer and is the most commonly included cancer-related symptom in core outcome sets for cancer research.
For measuring fatigue, the general fatigue subscale of the Multidimensional Fatigue Inventory (MFI-20), a 20-item self-report instrument, will be used.
The Dutch MFI-20 is a valid tool to assess cancer-related fatigue in breast cancer patients receiving oncological treatment.
This scale has a score from 20 to 100: higher scores indicate a higher level of fatigue.
|
one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
|
Pain (uncomfortable sensations in the body)
Time Frame: one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
The Brief Pain Inventory (BPI) is a 14-item questionnaire developed by the World Health Organization Collaborating Centre for Symptom Evaluation in Cancer Care to assess the worst pain, pain severity, and pain interference in cancer patients over the past week reported on a scale of 0 to 10. Pain interference is measured as the average of the 7 interference items, such as walking, mood, and sleep.
The BPI is the most common, reliable, and valid outcome measure to assess pain in cancer patients (Cronbach's a and test-retest reliability score > 0.80).
|
one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
|
Quality of Life (the degree to which an individual is healthy, comfortable, and able to participate in or enjoy life events)
Time Frame: one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) is a 30-item cancer-specific questionnaire developed for the assessment of the quality of life in cancer patients.
The EORTC QLQ-C30 is the most commonly used patient-reported outcome in breast cancer studies, has been translated and validated in over 100 languages, and shows acceptable psychometric properties.
All of the scales and single-item measures range in score from 0 to 100.
A high scale score represents a higher response level.
|
one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
|
Subjective level of physical activity
Time Frame: one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
Physical activity of the participants will be assessed with the short form of the International Physical Activity Questionnaire (IPAQ-SF), which subjectively assesses physical activity over the past 7 days.
The Dutch version of the IPAQ shows good reliability and validity.
|
one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
|
The feeling of perceived injustice
Time Frame: one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
For measuring the feeling of perceived injustice, the Injustice Experience Questionnaire (IEQ) will be used.
Participants have to rate the frequency of 12 different statements on a 5-point Likert scale ranging from 0 (not at all) to 4 (all the time), giving a total score that ranges from 0 to 48.
The Dutch version of the IEQ is valid and has good (test-retest) reliability (ICC = 0.86-0.87).
|
one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
|
Self-efficacy (self-beliefs to cope with a variety of difficult demands in life)
Time Frame: one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
The General Self-Efficacy Scale is a short 10-item scale for assessing optimistic self-beliefs to cope with a variety of difficult demands in life (such as cancer and its treatment), which is widely used, translated, and validated in many languages.
This scale has a score from 0 to 90: a higher number on this scale means higher self-efficacy.
|
one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
|
Healthcare and medication use during the study period
Time Frame: one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
The healthcare and medication use during the study period, including the use of co-interventions, will be registered with a modified version of the Medical Consumption Questionnaire.
This is a generic instrument for measuring the patients' total medical consumption, including additional diagnostics, healthcare visits, hospitalization, physiotherapy, medication, and aids (prescribed by the general practitioner or purchased by the patients themselves).
|
one day before the start of the intervention, one week after completion of the intervention, 30 days after breast surgery, 6 months after breast surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jo Nijs, Prof. Dr, Vrije Universiteit Brussel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KOTK/2022/12550
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
Clinical Trials on Patient-centered teleprehabilitation
-
CNGE ConseilRecruitingColorectal Cancer ScreeningFrance
-
University of PennsylvaniaCompletedGeneral Medical Inpatient ConditionsUnited States
-
Public Health Foundation Enterprises, Inc.ViiV Healthcare; San Francisco Department of Public Health; Lyon-Martin Community...Active, not recruiting
-
University of OuluOulu University HospitalNot yet recruitingHealth, Subjective | Cost EffectivenessFinland
-
Sint MaartenskliniekRadboud University Medical CenterCompletedMusculoskeletal Diseases | Rheumatoid ArthritisNetherlands
-
Johns Hopkins UniversityPatient-Centered Outcomes Research InstituteCompletedVenous Thromboembolism | Pulmonary Embolism | Deep Venous ThrombosisUnited States
-
King Abdullah International Medical Research CenterHarvard UniversityCompleted
-
Cook County HealthAgency for Healthcare Research and Quality (AHRQ)CompletedMultiple Co-morbiditiesUnited States
-
Philipps University Marburg Medical CenterCompleted
-
University of ChicagoCompleted